Corvus Pharmaceuticals, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2023 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 15, 2023. The record date for the meeting was April 18, 2023, with 46,568,511 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals. A total of 36,151,036 shares were voted in person or by proxy. The results were as follows:
- Proposal 1 (Election of Directors): Stockholders elected Class I director nominees Richard A. Miller, M.D., and Linda S. Grais, M.D., J.D. to serve until the 2026 Annual Meeting. Significant broker non-votes (10,073,471 shares) were recorded for this proposal.
- Proposal 2 (Ratification of Accounting Firm): Stockholders ratified the selection of PricewaterhouseCoopers LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Proposal 3 (Executive Compensation): Stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Verify the specific terms of the director nominees' tenure and any potential conflicts of interest.
- Confirm the scope of services and fees associated with the ratification of PricewaterhouseCoopers LLC.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 28, 2023) for detailed executive compensation data referenced in Proposal 3.
- Note the high volume of broker non-votes (10,073,471 shares) on the director election and executive compensation proposals.